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viral load (<16,000 copies/10s); Group 3 (n--4) sta- 
ble, high viral load (>16,000 copiesl10S); Group 4 
(n--4) history of PTLD, no detectable/low viral 
load. Flow cytometric analysis with HLA-A2 or -B8 
tetramer (TMR) probes was performed on periph- 
eral blood. The polarization of EBV-specific CD8+T 
cells (IFN-glIL-511L-10) was assessed by ELISPOT or 
ELISA. 
Results: Overall, the "lytic" specific CD8+T cells 
were more frequent than the "latent" ones and 
displayed distinct memory phenotypes (Effector 
Memory vs Central Memory). In addition, higher 
EBV loads triggered higher frequencies of TMR+ 
cells (G2 = G3 ~ G1), while patients with history 
of PTLD (G4) maintained high TMR+ frequencies. 
Interestingly, although patients in groups G2, G3 
and G4 had high frequencies of "lytic" TMR+ cells 
(1.3+2% vs 2.3+3.4% vs 1.1-1-0.9%), G2 and G4 ex- 
hibited higher frequencies of IFN-y producing cells 
(30+30 and 32+23 spots/10s), suggesting func- 
tional EBV-memory CDS+T cells, while G3 displayed 
impaired IFN-y (19+31 spots/10s), indicative of 
functional exhaustion. Although EBV stimulation 
triggered preponderantly IFN-y, the IFN-y/IL-5 ra- 
tio was lower in all patients (2.5:1) as compared 
to adult controls (5:1) yet another unique feature 
of immune responses in pediatric patients. CDS+T 
cells in G3 produced higher levels of IL-10 as com- 
pared to other groups. 
Conclusion: These results demonstrate significant 
differences in EBV-specific memory CDS+T cells 
from pediatric HTx patients based on their EBV 
clinical/viral load status. The functional impair- 
ment of CDS+T cells from G3 patients might be 
either a direct result of chronic EBV challenge, or 
might be due to biased polarization (intermediate 
IL-5) or to Treg development (high IL-10). 
25 
Chronic Rhinoviral Infection in Lung Transplant 
Recipients 
C. Deffernez, P.M. Soccal, J-D. Aubert, J-C. Pache, 
T. Rochat, J. Garbino, W. Wunderli, P. Meylan, 
S. Yerly, L. Perrin, I. Letovanec, L. Nicod, 
C. Tapparel, L. Kaiser*. Central Laboratory 
of Virology, Division of Infectious Diseases, 
Department of Internal Medicine, University 
Hospitals of Geneva Rue Micheli-du-Crest 24, 1211 
Geneva 14, Switzerland 
Background: [?hinovirus is the most frequent res- 
piratory virus circulating in the community. Lung 
transplant recipients with viral respiratory tract in- 
fections are at risk of complications and protracted 
diseases. 
Objective: To describe lung transplant recipients 
chronically infected by rhinovirus. 
Methods: We first identified an index case and 
confirmed by sequencing viral isolates that he was 
chronically infected by rhinovirus. Then we con- 
ducted a prospective study to assess the incidence 
and the potential clinical impact of chronic rhi- 
noviral infections in a cohort of 68 lung transplant 
recipients. Sequence analysis of viral isolates (all 
cases) as well immunochemistry on lung biopsies 
(in one case) have been performed. 
Results: We describe 3 lung transplant recipients 
chronically infected by rhinovirus over a period of 
one year. Rhinovirus was mainly identified by RT- 
PCR but full virions were also isolated repeatedly 
in one case. The persistence of a unique strain 
was confirmed by the analysis of the 5'NCR and 
VP1 genes sequences and ruled-out re-infections. 
All cases presented lower respiratory symptoms as 
well as graft dysfunctions, 2 had repeated acute 
rejections episodes, and 2 died. In one case that 
failed to produce neutralizing antibodies we also 
showed the presence of rhinovirus within the lower 
respiratory tract parenchyma. Over a period of 19 
months rhinoviral infections, screened in broncho- 
laveolar lavages, were documented in approxi- 
mately 15% of cases; one fifth of them presented a
persistent infection. 
Conclusions: In lung transplant recipients with 
graft dysfunction we have documented that rhi- 
noviral infection can be persistent. [?hinovirus was 
detected in the lung parenchyma in one case. Our 
investigation suggests that rhinovirus contributed 
to the graft dysfunctions. 
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Back~Iround: Human-coronaviruses (HCoV) are the 
most frequent cause of upper respiratory infections 
after rhinoviruses. HCoV are also associated with 
lower respiratory tract symptoms and protracted 
disease in subjects at risk. Until recently only 
HCoV-OC43 and 229E were known in humans. The 
impact of the recently discovered HCoV-NL63 and 
HKUI in hospitalized adults needs to be estab- 
lished. 
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Objectives: To assess the cLinicaL impact of the 4 
human HCoVs in hospitalized patients. 
Methods: ALL patients of our university hospi- 
tals who needed a bronchoatveotar-tavage (BAL) 
for an acute respiratory event were enroLLed. 
BAL specimens were screened by RT-PCR for 
the presence of HCoV-OC43, 229E, NL63 and 
HKU1 and ten other respiratory viruses (influenza 
A-B, respiratory syncytial virus A-B, parainfluenza 
1-2-3, hurnan-rhinovirus, enterovirus and human- 
metapneumovirus ) a  welt as Mycoplasma pneumo- 
niae, Chlamydophila pneumoniae and Legionella 
pneumophila. 
Results: There were 539 cases enroLLed in the 
study and 29 (5.4%) had an HCoV identified in 
the BAL specimen. HCoV-OC43 was the most fre- 
quent (n = 12) foLLowed by HCoV-229E (n = 7), HCoV- 
NL63 (n=6) and HCoV-HKU1 (n=4). The median 
age was 47 years and 69% of the cases were male. 
TranspLantation was the most frequent underlying 
diseases and only 28% patients were not considered 
as immunosuppressed. The microbioLogicaL cultures 
of the BAL were negative for bacteria in 69% cases 
and no other respiratory viruses or herpes were 
identified. Nine patients (31%) were in the intensive 
care unit at the time of the BAL procedure (eight 
of them on mechanical ventilation). Twenty-one 
(72%) patients presented acute respiratory symp- 
toms, sixteen (55%) had cough and sputum, and 
13 (45%) dyspnea. A new chest X-ray infiltrate was 
documented in 18 patients (62%) at the time of the 
BAL procedure. Fifteen (52%) patients were already 
treated for a respiratory infection at the time of 
the BAL. The most frequent final diagnosis was a 
Lower respiratory tract infection that remained of 
unspecified etiology in one third of cases. 
Conclusion: ALL four HCoVs are recovered in bron- 
chotaveotar ravages of hospitalized patients. Our 
analysis uggests that they contributed to respira- 
tory symptoms in most cases. 
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Background: Previous tudies have shown that the 
Live attenuated Towne CMV vaccine improved graft 
survival in CMV seronegative r nal transplant recip- 
ients of CMV seropositive donor organs. However, 
the Towne vaccine is not avaiLabLe and recombinant 
vaccines are being developed. TriaLs have demon- 
strated that recombinant gtycoprotein B CMV vac- 
cine (CMVgB) when combined with the adjuvant 
MF 59 is immunogenic and safe in normal individu- 
aLs. 
Objective: To assess the safety and immunogenic- 
ity of the EMVgB vaccine in immunocompromised 
individuals with renal failure on dialysis, who are 
awaiting renal transplantation. 
Methods: A mutticenter, randomized, placebo- 
controLLed trial in EMV seronegative patients with 
renal failure on transplant Lists. Randomization was 
2:2:1 with doses of EMVgB vaccine at either 20 mcg, 
100 mcg or placebo. Injections were administered 
by intramuscular injection at 0, 1 and 6 months 
post enroLLment. Sera were obtained at enroLL- 
ment, and 1, 1.5, 3, 6, 6.5, 8, and 12 months. 
Patients transplanted post enroLLment were fob 
Lowed but did not continue immunization. Sera 
were tested for antibody to EMVgB by ELISA, and 
for neutralizing antibody to EMV. OnLy a Limited set 
of sera were tested before the trial was halted by 
the sponsor due to stow enroLLment. 
Results: 46 patients were enroLLed: 18 received 
20 mcg per dose, 19 received 100 mcg per dose and 
9 received placebo. Patients were weLL matched for 
degree of renal failure and age. Renal transptanta- 
tion occurred in 14 patients. NeutraLizing antibody 
was transiently present in 1 of 5 patients who 
received 3 doses of the 20 mcg dose. In 5 patients 
who received 3 doses at 100 mcg, neutralizing an- 
tibody was detected in 3 of 5 at titers that ranged 
from 35 to 57. Two patients in the 100mcg dose 
group developed CMV syndromes post transpLanta- 
tion both received only 2 doses of vaccine prior 
to transplantation. A neutralizing antibody titer of 
248 was detected 4 months after infection in one 
subject, the other was not tested. No significant 
adverse events were noted with injections in any 
subject. 
Conclusions: The CMVgB vaccine was safe. Some 
evidence of neutralizing antibody could be de- 
tected in patients at the 100mcg dose. Two pa- 
tients who did not complete the 3 dose series 
developed CMV infection and syndrome. Future 
studies may need to incorporate Larger doses of 
vaccine or an improved adjuvant or both. 
